Nuvation Bio Inc. Debt Securities, Available-for-sale, Amortized Cost
Nuvation Bio Inc. (NUVB) had Debt Securities, Available-for-sale, Amortized Cost of $423.61 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $423.61M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $496.42M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $460.68M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $529.45M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $423.61M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $496.42M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $460.68M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $529.45M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $559.42M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $430.06M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $478.48M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $526.27M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $563.85M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $586.40M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $594.89M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $618.14M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $609.98M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $647.14M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $633.75M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $663.23M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $678.14M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $688.89M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $719.03M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $446.76M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $356.32M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $184.83M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $194.84M 10-K · filed 2022-02-28 | $184.44M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |